• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer

Opinion
Video

A breast medical oncologist reviews oral SERDs currently in development for the treatment of patients with ER+/HER2 metastatic breast cancer, highlighting camizestrant, imlunestrant, and giredestrant.

Related Videos
5 experts are featured in this series
5 experts are featured in this series
1 expert is featured in this series.
5 experts are featured in this series.
5 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.